ImmunSYS

Executive Summary

ImmunSYS is a San Diego-based biotechnology company founded in 2017, dedicated to developing novel immunotherapies that correct immune system dysregulation. The company's primary focus is on autoimmune and inflammatory diseases, a therapeutic area with significant unmet medical need. ImmunSYS leverages proprietary platforms to design biologics that modulate immune responses, aiming to restore homeostasis in patients with conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease. While the company remains in early-stage development with no publicly disclosed pipeline or funding details, its strategic location in a major biotech hub and emphasis on immune modulation position it within a competitive but rapidly evolving field. The company's progress will depend on advancing lead candidates into preclinical studies and securing partnerships or financing to support clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data40% success
• Q3 2026Series A Financing or Grant Award50% success